182 related articles for article (PubMed ID: 33145297)
1. Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors.
Chai R; Fan Y; Zhao J; He F; Li J; Han Y
Ann Transl Med; 2020 Sep; 8(17):1078. PubMed ID: 33145297
[TBL] [Abstract][Full Text] [Related]
2. Exploration of a novel prognostic model based on nomogram in non-small cell lung cancer patients with distant organ metastasis: implications for immunotherapy.
Wang M; Zhang Y; Liu M; Wang Y; Niu X; Qiu D; Xi H; Zhou Y; Chang N; Xu T; Xing L; Yamauchi Y; Terra RM; Tane S; Moon MH; Yan X; Zhao F; Zhang J
Transl Lung Cancer Res; 2023 Oct; 12(10):2040-2054. PubMed ID: 38025819
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Dynamic Nomogram Integrated with Inflammation-Based Factors for Non-Small Cell Lung Cancer Patients with Chronic Hepatitis B Viral Infection.
Chen S; Li X; Lv H; Wen X; Ding Q; Xue N; Su H; Chen H
Int J Biol Sci; 2018; 14(13):1813-1821. PubMed ID: 30443185
[TBL] [Abstract][Full Text] [Related]
4. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
5. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
Diker O; Olgun P; Balyemez U; Sigit Ikiz S
Cureus; 2023 Jan; 15(1):e33234. PubMed ID: 36733552
[TBL] [Abstract][Full Text] [Related]
6. Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospective study.
Wen S; Du X; Chen Y; Xia J; Wang R; Zhu M; Peng W; Spitaleri G; Hofman P; Bironzo P; Wang X; Shen B
Transl Lung Cancer Res; 2022 May; 11(5):757-775. PubMed ID: 35693285
[TBL] [Abstract][Full Text] [Related]
7. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer.
Huang H; Chen Y; Weng X; Li S; Zhang L; Chen P
Cancer Cell Int; 2022 Aug; 22(1):261. PubMed ID: 35989349
[TBL] [Abstract][Full Text] [Related]
9. [Establishment and validation of a predictive nomogram model for advanced gastric cancer with perineural invasion].
Liu SH; Hou XY; Zhang XX; Liu GW; Xin FJ; Wang JG; Zhang DL; Wang DS; Lu Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1059-1066. PubMed ID: 33212554
[No Abstract] [Full Text] [Related]
10. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
11. [Peripheral Blood Inflammation Indicators as Predictive Indicators in
Immunotherapy of Advanced Non-small Cell Lung Cancer].
Xia J; Chen Y; Wen S; Du X; Shen B
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):632-645. PubMed ID: 34521188
[TBL] [Abstract][Full Text] [Related]
12. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
13. Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.
Du X; Bai H; Wang Z; Daun J; Liu Z; Xu J; Chang G; Zhu Y; Wang J
Thorac Cancer; 2022 May; 13(9):1289-1298. PubMed ID: 35347870
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Zeng H; Huang WW; Liu YJ; Huang Q; Zhao SM; Li YL; Tian PW; Li WM
Front Oncol; 2021; 11():685047. PubMed ID: 34458139
[TBL] [Abstract][Full Text] [Related]
16. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():849468. PubMed ID: 35669769
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
19. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer.
Zhang S; Pease DF; Kulkarni AA; Kumar M; Shanley RM; Xu B; Joshi SP; Patel MR
Clin Med Insights Oncol; 2021; 15():11795549211004489. PubMed ID: 34248362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
